Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP Sells $47,424.02 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote sold 2,437 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the sale, the senior vice president now owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Travere Therapeutics Trading Up 6.9 %

NASDAQ:TVTX traded up $1.35 during trading hours on Thursday, hitting $20.81. The company had a trading volume of 2,031,403 shares, compared to its average volume of 1,331,242. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $20.89. The company has a market capitalization of $1.62 billion, a PE ratio of -4.57 and a beta of 0.70. The stock has a 50-day moving average price of $18.28 and a 200 day moving average price of $14.79.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. During the same quarter in the previous year, the firm posted ($1.17) EPS. The company’s revenue for the quarter was up 69.6% compared to the same quarter last year. On average, equities research analysts predict that Travere Therapeutics, Inc. will post -3.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Creative Planning boosted its position in shares of Travere Therapeutics by 4.3% during the third quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after purchasing an additional 995 shares in the last quarter. Forefront Analytics LLC boosted its holdings in shares of Travere Therapeutics by 10.2% during the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after buying an additional 1,237 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Travere Therapeutics in the 4th quarter worth about $53,000. CWM LLC lifted its position in Travere Therapeutics by 158.5% during the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after acquiring an additional 3,065 shares during the period. Finally, Diversified Trust Co boosted its stake in Travere Therapeutics by 27.5% during the fourth quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock worth $256,000 after acquiring an additional 3,169 shares in the last quarter.

Analysts Set New Price Targets

Several analysts have weighed in on TVTX shares. Bank of America boosted their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Scotiabank boosted their target price on Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on Travere Therapeutics in a research report on Friday, January 10th. They set an “overweight” rating on the stock. Citigroup lowered their price objective on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Finally, Wedbush raised their target price on shares of Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.